688331 荣昌生物
已收盘 12-31 15:00:00
资讯
新帖
简况
荣昌生物（688331）披露2022年及2023年A股限制性股票激励计划归属条件成就公告，12月29日股价下跌0.48%
证券之星 · 2025-12-29
荣昌生物（688331）披露2022年及2023年A股限制性股票激励计划归属条件成就公告，12月29日股价下跌0.48%
每周股票复盘：荣昌生物（688331）拟回购2000万至4000万元股份
证券之星 · 2025-12-28
每周股票复盘：荣昌生物（688331）拟回购2000万至4000万元股份
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
荣昌生物(09995.HK)涨超3%
每日经济新闻 · 2025-12-23
荣昌生物(09995.HK)涨超3%
港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力
智通财经 · 2025-12-23
港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力
荣昌生物拟回购 金额2000万元至4000万元
财中社 · 2025-12-22
荣昌生物拟回购 金额2000万元至4000万元
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
时代财经 · 2025-12-22
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
荣昌生物：关于取得金融机构股票回购专项贷款承诺函的公告
证券日报 · 2025-12-18
荣昌生物：关于取得金融机构股票回购专项贷款承诺函的公告
荣昌生物：第二届董事会第三十二次会议决议公告
证券日报 · 2025-12-15
荣昌生物：第二届董事会第三十二次会议决议公告
荣昌生物(688331.SH)拟以2000万元至4000万元回购股份
智通财经 · 2025-12-15
荣昌生物(688331.SH)拟以2000万元至4000万元回购股份
港股异动 | 荣昌生物(09995)盘中涨超7% 公布PD-1/VEGF双抗非小细胞肺癌临床数据
智通财经 · 2025-12-11
港股异动 | 荣昌生物(09995)盘中涨超7% 公布PD-1/VEGF双抗非小细胞肺癌临床数据
医药股普遍回暖 荣昌生物(09995)涨4.26% 交银国际料明年内地医药板块稳中向好态势延续
金吾财讯 · 2025-12-04
医药股普遍回暖 荣昌生物(09995)涨4.26% 交银国际料明年内地医药板块稳中向好态势延续
荣昌生物(09995)涨逾4%终结三连阴 此前获贝莱德大手增持 机构指其正快速向盈亏平衡点靠拢
金吾财讯 · 2025-12-04
荣昌生物(09995)涨逾4%终结三连阴 此前获贝莱德大手增持 机构指其正快速向盈亏平衡点靠拢
核心高管精准减持“撤离”，控股股东却被“锁仓”，荣昌生物何时才能盈利？｜创新药观察
华夏时报网 · 2025-12-03
核心高管精准减持“撤离”，控股股东却被“锁仓”，荣昌生物何时才能盈利？｜创新药观察
【券商聚焦】中泰证券维持荣昌生物(09995)“增持”评级 指其正处在商业化能力加速兑现的通道上
金吾财讯 · 2025-12-03
【券商聚焦】中泰证券维持荣昌生物(09995)“增持”评级 指其正处在商业化能力加速兑现的通道上
荣昌生物（688331）披露预计2026-2028年度日常关联交易议案，12月02日股价下跌2.11%
证券之星 · 2025-12-02
荣昌生物（688331）披露预计2026-2028年度日常关联交易议案，12月02日股价下跌2.11%
荣昌生物遭贝莱德减持18.55万股 每股作价约81.64港元
新浪港股 · 2025-12-01
荣昌生物遭贝莱德减持18.55万股 每股作价约81.64港元
贝莱德减持荣昌生物(09995)18.55万股 每股作价约81.64港元
智通财经 · 2025-11-28
贝莱德减持荣昌生物(09995)18.55万股 每股作价约81.64港元
港股异动 | 荣昌生物(09995)午后涨超7% 泰它西普快速放量 维迪西妥联合免疫疗效优异
智通财经 · 2025-11-27
港股异动 | 荣昌生物(09995)午后涨超7% 泰它西普快速放量 维迪西妥联合免疫疗效优异
荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行 转仓市值8.96亿港元
智通财经 · 2025-11-27
荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行 转仓市值8.96亿港元
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":77.79,"timestamp":1767164400000,"preClose":77.37,"halted":0,"volume":5829280,"delay":0,"changeRate":0.0054,"floatShares":162000000,"shares":564000000,"eps":-1.6811,"marketStatus":"已收盘","change":0.42,"latestTime":"12-31 15:00:00","open":77.35,"high":78.24,"low":75.03,"amount":445000000,"amplitude":0.0415,"askPrice":77.8,"askSize":39,"bidPrice":77.79,"bidSize":33,"shortable":0,"etf":0,"ttmEps":-1.6811,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":77.37,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":85.11,"lowLimit":69.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":563710243,"isCdr":false,"pbRate":18.9,"roa":"--","roe":"--","epsLYR":-2.73,"committee":-0.68951,"marketValue":43851000000,"turnoverRate":0.0359,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-05。","afterMarket":{"amount":0,"volume":0,"close":77.79,"buyVolume":0,"sellVolume":0,"time":1767166437558,"indexStatus":"已收盘 12-31 15:30:00","preClose":77.37},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":73.65,"timestamp":1767341326010,"preClose":72,"halted":0,"volume":601950,"delay":0,"premium":"-15.35"},"floatMarketCap":12627000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2595866467","title":"荣昌生物（688331）披露2022年及2023年A股限制性股票激励计划归属条件成就公告，12月29日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595866467","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595866467?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:37","pubTimestamp":1767001039,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，荣昌生物报收于78.75元，较前一交易日下跌0.48%，最新总市值为443.92亿元。该股当日开盘79.3元，最高80.53元，最低78.5元，成交额达3.38亿元，换手率为2.63%。公司近日发布公告称，第二届董事会第三十三次会议审议通过多项议案。此外，董事会认为2023年A股限制性股票激励计划首次授予第一个归属期的归属条件已达成，同意办理归属，并作废该计划中部分离职激励对象已获授但尚未归属的限制性股票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900023766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK1161","09995","688331","BK1574","LU1064131003.USD","LU2488822045.USD","159982","BK1583","LU1969619763.USD","LU2148510915.USD","LU2328871848.SGD","399300","BK0239"],"gpt_icon":0},{"id":"2594147241","title":"每周股票复盘：荣昌生物（688331）拟回购2000万至4000万元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2594147241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594147241?lang=zh_cn&edition=full","pubTime":"2025-12-28 01:48","pubTimestamp":1766857693,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，荣昌生物报收于79.13元，较上周的82.4元下跌3.97%。本周，荣昌生物12月22日盘中最高价报82.79元。本周关注点公司公告汇总：荣昌生物计划以集中竞价方式回购股份，金额不低于2000万元且不超过4000万元。公司公告汇总：本次回购股份价格不超过95元/股，期限为董事会审议通过之日起12个月内。本次回购股份拟用于员工持股计划或股权激励，若3年内未使用完毕，未使用部分将注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2488822045.USD","BK1574","LU1969619763.USD","09995","BK1583","LU1064131003.USD","LU2148510915.USD","LU2328871848.SGD","BK0239","LU1064130708.USD","688331","BK1161"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","600276","LU0405327148.USD","06978","LU1997245177.USD","LU2097828474.EUR","BK1593","LU1146622755.USD","LU1997245094.SGD","LU2495084118.USD","02142","02509","688336","BK0196","BK1589","LU2097828631.EUR","09995","LU0502904849.HKD","000661","LU1064131003.USD","LU2148510915.USD","BK0057","BK0060","BK0012","LU1781817850.SGD","02096","LU1997244956.HKD","688062","LU2488822045.USD","688331","LU1969619763.USD","LU2097828714.EUR","LU2097828557.USD","01530","BK1574","01167","688428","LU2580892862.HKD","BK0239","BK1161","LU2097828805.USD","LU1328615791.USD","BK0028","BK0183","603087","01801","BK0188","03692","002755","LU0405327494.USD"],"gpt_icon":0},{"id":"2593245061","title":"荣昌生物(09995.HK)涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593245061","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593245061?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:13","pubTimestamp":1766456035,"startTime":"0","endTime":"0","summary":"每经AI快讯，荣昌生物(09995.HK)涨超3%，截至发稿涨3.41%，报78.8港元，成交额9838.12万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599267548.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599267548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09995","LU1064130708.USD","BK1583","LU1969619763.USD","688331","BK1574","LU2148510915.USD","LU1064131003.USD","LU2328871848.SGD","LU2488822045.USD","BK0239","BK1161"],"gpt_icon":0},{"id":"2593457234","title":"港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2593457234","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593457234?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:02","pubTimestamp":1766455373,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物涨超3%，截至发稿，涨3.41%，报78.8港元，成交额9838.12万港元。研究数据显示，RC148单药与联合方案均显示出突出的临床疗效和可控的安全性，实现了双路径突破。目前公司正在积极推进相关临床：根据公司投资者调研纪要，RC148联合治疗一线非小细胞肺癌的II期临床试验已完成患者入组并计划启动联合治疗非小细胞肺癌的Ⅲ期临床研究，看好后续临床潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","BK1574","BK0239","BK1583","LU2328871848.SGD","688331","LU2148510915.USD","LU1969619763.USD","LU2488822045.USD","09995","BK1161","LU1064130708.USD"],"gpt_icon":0},{"id":"2593483499","title":"荣昌生物拟回购 金额2000万元至4000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483499","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483499?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:21","pubTimestamp":1766395284,"startTime":"0","endTime":"0","summary":"12月22日，荣昌生物（688331/09995）发布公告，计划以集中竞价交易方式回购股份，回购金额不低于2000万元且不超过4000万元，回购价格上限为95元/股，回购股份将用于员工持股计划或股权激励，回购期限为自董事会审议通过之日起12个月内。2025年前三季度，荣昌生物实现收入17.20亿元，归母净利润-5.51亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598357980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","BK0239","BK1161","09995","LU1064130708.USD","688331","BK1574","BK1583","LU2148510915.USD","LU1064131003.USD","LU2488822045.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2593483856","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483856","media":"时代财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483856?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:58","pubTimestamp":1766393880,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂 JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251222/c673401182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688428","BK0239","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","LU2488822045.USD","688331","688235"],"gpt_icon":0},{"id":"2592903581","title":"荣昌生物：关于取得金融机构股票回购专项贷款承诺函的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903581","media":"证券日报","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592903581?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:07","pubTimestamp":1766059669,"startTime":"0","endTime":"0","summary":"证券日报网讯12月18日晚间，荣昌生物发布公告称，近日，公司取得招商银行股份有限公司烟台分行出具的《贷款承诺函》，主要内容如下：1、贷款承诺额度：不超过人民币3600万元且不超过实际回购金额的90%；2、贷款期限：不超过36个月；3、贷款用途：专项用于回购公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595657981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4211","BK1574","09995","FISI","LU1064130708.USD","BK1583","LU1064131003.USD","LU1969619763.USD","LU2148510915.USD","LU2488822045.USD","BK1161","688331","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591641505","title":"荣昌生物：第二届董事会第三十二次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641505","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591641505?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:05","pubTimestamp":1765803918,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日晚间，荣昌生物发布公告称，公司第二届董事会第三十二次会议审议通过《关于以集中竞价交易方式回购公司股份方案的议案》等多项议案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591974866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LU2148510915.USD","LU2328871848.SGD","LU2488822045.USD","09995","LU1064131003.USD","688331","LU1064130708.USD","BK0239","BK1161","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2591054614","title":"荣昌生物(688331.SH)拟以2000万元至4000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591054614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591054614?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:32","pubTimestamp":1765791179,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(688331.SH)发布公告，公司拟以2000万元至4000万元回购股份，回购股份价格不超过95元/股，回购的股份拟用于员工持股计划或股权激励。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","LU2328871848.SGD","LU1064130708.USD","BK0239","LU1969619763.USD","09995","BK1161","LU2488822045.USD","LU1064131003.USD","LU2148510915.USD","688331"],"gpt_icon":0},{"id":"2590563981","title":"港股异动 | 荣昌生物(09995)盘中涨超7% 公布PD-1/VEGF双抗非小细胞肺癌临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590563981","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590563981?lang=zh_cn&edition=full","pubTime":"2025-12-11 10:45","pubTimestamp":1765421137,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物盘中涨超7%，截至发稿，涨5.57%，报81.5港元，成交额3.1亿港元。会上，由荣昌生物自主研发的PD-1/VEGF双特异性抗体RC148单药及联合方案一线或二线治疗非小细胞肺癌的一项Ⅰ/Ⅱ期临床研究数据，以壁报形式正式发布。据悉，今年8月，RC148已获FDA批准在美国开展II期临床试验。获得FDA的IND许可，标志着该药将进入全球临床开发阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","PD","BK1574","09995","BK0239","BK1161","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","BK4023","LU1169589451.USD","LU2488822045.USD","688331","BK1583","LU1969619763.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2588074906","title":"医药股普遍回暖 荣昌生物(09995)涨4.26% 交银国际料明年内地医药板块稳中向好态势延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2588074906","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588074906?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:58","pubTimestamp":1764817092,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股普遍回暖，荣昌生物 涨4.26%，康方生物涨3.89%，金斯瑞生物科技涨3.11%，康诺亚-B涨2.95%，科伦博泰生物-B涨2.45%，诺诚健华涨1.79%，药明生物涨1.63%，泰格医药涨1.38%，药明康德涨1.33% 。交银国际发表报告指，予内地医药行业领先评级。如该行此前预期，内地医药行业2025年迎来关键转折。2026年，该行认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970883","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880383366.USD","BK0239","LU1720050803.USD","LU2242644610.SGD","09969","688331","LU2399975544.HKD","LU0307460666.USD","03347","02269","01548","BK1161","02162","HK0000320264.USD","LU2476274720.SGD","LU2328871848.SGD","LU0516423091.SGD","LU2039709279.SGD","LU0359202008.SGD","LU1688375341.USD","09926","LU0359201612.USD","09995","159938","02359","BK1589","LU0417516571.SGD","BK1587","LU0326950275.SGD","LU0588546209.SGD","LU0856984785.SGD","LU1961090484.USD","IE00BPRC5H50.USD","LU0181495838.USD","LU2148510915.USD","LU0819121731.USD","BK1515","LU0634319403.HKD","BK1610","LU2488822045.USD","BK1141","BK1574","06990","LU0516422952.EUR","09939","LU0561508036.HKD","LU0823426308.USD","03329","LU0052750758.USD","LU1046422090.SGD"],"gpt_icon":0},{"id":"2588407102","title":"荣昌生物(09995)涨逾4%终结三连阴 此前获贝莱德大手增持 机构指其正快速向盈亏平衡点靠拢","url":"https://stock-news.laohu8.com/highlight/detail?id=2588407102","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588407102?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:33","pubTimestamp":1764815583,"startTime":"0","endTime":"0","summary":"金吾财讯 | 荣昌生物(09995)早盘股价反弹回升，终结此前日线图三连阴，截至发稿，报88港元，涨4.2%，成交额1.11亿港元。消息面上，根据香港联交所11月28日披露的文件，贝莱德(BlackRock, Inc.)于11月24日以每股均价82.9384港元增持461.3万股H股股份，价值约3.83亿港元。增持后，贝莱德最新持股数目为1,057.95万股股份，好仓比例由2.86%升至5.07%。中泰证券研报指，荣昌生物正处在商业化能力加速兑现的通道上，通过高效的运营和精准的投入，公司正快速向盈亏平衡点靠拢。维持“增持”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970881","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0157215616.USD","LU1670627923.USD","LU0130102774.USD","IE00B3PB1722.GBP","IE00BDGV0183.EUR","LU2328871848.SGD","LU1509826696.USD","LU1599440770.SGD","BK1161","LU1481011671.HKD","IE00BVYPNV92.GBP","LU1366333091.USD","BK4534","LU0742537680.HKD","LU1064130708.USD","IE00B64PRP62.GBP","IE00BVYPNW00.USD","LU0731783394.SGD","LU1969619763.USD","LU2488822045.USD","BK1574","LU0980610538.SGD","LU1064131003.USD","BK4135","IE00BGHQF748.EUR","LU0070302665.USD","LU2430703251.USD","LU0208291251.USD","BK4585","LU1280957306.USD","LU2505996509.AUD","LU2264538146.SGD","BK4567","BK4533","LU1201861249.SGD","BK4588","BLK","LU0772969993.USD","BK4504","IE00BGHQF631.EUR","LU0320765489.SGD","LU2505996681.GBP","IE00B42XCP33.USD","09995","LU0648001328.SGD","LU0640476718.USD","BK4581","BK1583","IE00B3QW5Z07.USD","688331"],"gpt_icon":0},{"id":"2588045496","title":"核心高管精准减持“撤离”，控股股东却被“锁仓”，荣昌生物何时才能盈利？｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045496","media":"华夏时报网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588045496?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:23","pubTimestamp":1764764612,"startTime":"0","endTime":"0","summary":"2025年12月3日，一则荣昌生物制药（烟台）股份有限公司（下称“荣昌生物”，股票代码688331.SH、9995.HK）疑似减持受限的消息引起《华夏时报》记者注意。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512033581742820.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512033581742820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU1064131003.USD","LU2488822045.USD","688331","BK0239","06978","BK1161","09995","LU1064130708.USD","BK1574","LU2148510915.USD","159992","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2588090548","title":"【券商聚焦】中泰证券维持荣昌生物(09995)“增持”评级 指其正处在商业化能力加速兑现的通道上","url":"https://stock-news.laohu8.com/highlight/detail?id=2588090548","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588090548?lang=zh_cn&edition=full","pubTime":"2025-12-03 14:26","pubTimestamp":1764743192,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰证券研报指，荣昌生物 营业总收入17.20亿元；归母净利润-5.51亿元，亏损收窄，主要得益于核心产品的持续放量、销售和管理费用的有效控制，以及泰它西普海外临床费用转由合作方承担后带来的研发支出下降；销售毛利率84.27%，+4.52个百分点，研发费用8.91亿元。荣昌生物正处在商业化能力加速兑现的通道上，通过高效的运营和精准的投入，公司正快速向盈亏平衡点靠拢。维持“增持”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970822","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","600918","688331"],"gpt_icon":0},{"id":"2588960059","title":"荣昌生物（688331）披露预计2026-2028年度日常关联交易议案，12月02日股价下跌2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588960059","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588960059?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:17","pubTimestamp":1764685032,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，荣昌生物报收于93.23元，较前一交易日下跌2.11%，最新总市值为525.55亿元。该股当日开盘94.0元，最高95.97元，最低92.96元，成交额达2.55亿元，换手率为1.67%。公司近日发布公告称，荣昌生物制药（烟台）股份有限公司于2025年12月2日召开2025年第三次临时股东会，会议审议通过《关于预计2026-2028年度日常关联交易的议案》及《关于修订公司部分治理制度的议案》下的四项子议案。出席会议的股东共180人，代表表决权股份占公司总表决权的47.5817%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2488822045.USD","BK1574","LU1969619763.USD","09995","BK1583","LU1064131003.USD","LU2148510915.USD","LU2328871848.SGD","BK0239","LU1064130708.USD","688331","BK1161"],"gpt_icon":0},{"id":"2588115737","title":"荣昌生物遭贝莱德减持18.55万股 每股作价约81.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588115737","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588115737?lang=zh_cn&edition=full","pubTime":"2025-12-01 08:51","pubTimestamp":1764550260,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，11月25日，贝莱德减持荣昌生物（09995）18.55万股，每股作价81.6411港元，总金额约为1514.44万港元。减持后最新持股数目约为1041.11万股，最新持股比例为4.99%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-12-01/doc-infzhauh5174148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LU2505996509.AUD","BLK","LU0070302665.USD","IE00B3PB1722.GBP","LU0130102774.USD","LU0980610538.SGD","LU0731783394.SGD","LU1064130708.USD","LU1989771016.USD","LU2505996681.GBP","09995","LU2488822045.USD","IE00B3QW5Z07.USD","BK4588","BK4135","LU1481011671.HKD","BK1574","IE00BVYPNV92.GBP","LU1599440770.SGD","LU0742537680.HKD","LU1481011911.USD","LU0731783048.USD","LU1291159041.SGD","LU1969619763.USD","LU1074936037.SGD","LU2264538146.SGD","LU2430703095.HKD","LU2430703178.SGD","LU0157215616.USD","BK1583","LU0648001328.SGD","LU1064131342.USD","BK0239","BK1161","IE00BDGV0183.EUR","LU1064131003.USD","BK4567","IE00BGHQF631.EUR","IE00BVYPNW00.USD","LU1988902786.USD","LU2592432038.USD","LU1366333091.USD","LU2328871848.SGD","LU0640476718.USD","LU2430703251.USD","IE00B42XCP33.USD","BK4581","IE00B64PRP62.GBP","688331"],"gpt_icon":0},{"id":"2586841784","title":"贝莱德减持荣昌生物(09995)18.55万股 每股作价约81.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586841784","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586841784?lang=zh_cn&edition=full","pubTime":"2025-11-28 20:04","pubTimestamp":1764331478,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月25日，贝莱德减持荣昌生物(09995)18.55万股，每股作价81.6411港元，总金额约为1514.44万港元。减持后最新持股数目约为1041.11万股，最新持股比例为4.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2592432038.USD","IE00BVYPNV92.GBP","LU1599440770.SGD","LU2430703251.USD","LU2264538146.SGD","IE00B64PRP62.GBP","LU2505996509.AUD","LU1670628061.USD","BK1161","LU2328871848.SGD","IE00BVYPNW00.USD","IE00B3QW5Z07.USD","BK4535","BK4585","LU1509826696.USD","BK4135","BK4567","LU0208291251.USD","LU0648001328.SGD","BK4504","LU2505996681.GBP","09995","LU0320765489.SGD","LU1064131342.USD","LU1201861249.SGD","LU2430703178.SGD","IE00B3PB1722.GBP","IE00BDGV0183.EUR","LU0772969993.USD","LU0130102774.USD","LU1280957306.USD","LU0731783048.USD","BLK","LU0640476718.USD","LU1064131003.USD","LU0980610538.SGD","IE00BGHQF748.EUR","LU1988902786.USD","BK1574","LU0742537680.HKD","LU0731783394.SGD","LU1670627923.USD","LU0070302665.USD","LU1291159041.SGD","LU1989771016.USD","LU1074936037.SGD","LU2148510915.USD","BK4533","688331","LU1969619763.USD"],"gpt_icon":0},{"id":"2586219903","title":"港股异动 | 荣昌生物(09995)午后涨超7% 泰它西普快速放量 维迪西妥联合免疫疗效优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2586219903","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586219903?lang=zh_cn&edition=full","pubTime":"2025-11-27 13:39","pubTimestamp":1764221992,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物午后涨超7%，截至发稿，涨6.39%，报90.75港元，成交额3.19亿港元。甬兴证券发布研报称，维迪西妥联合免疫疗效优异，标志着尿路上皮癌治疗格局重大变革。中信建投发布研报称，2025年，核心产品泰它西普新增适应症获批后快速放量，维迪西妥单抗联合治疗方案数据优异，同时RC28的DME适应症上市申请获受理；在研管线中RC148获突破性疗法认定，临床数据持续验证价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","LU2328871848.SGD","BK0239","BK1161","BK1583","LU2488822045.USD","LU1064131003.USD","09995","LU1064130708.USD","LU1969619763.USD","BK1574","LU2148510915.USD"],"gpt_icon":0},{"id":"2586291653","title":"荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行 转仓市值8.96亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586291653","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586291653?lang=zh_cn&edition=full","pubTime":"2025-11-27 08:31","pubTimestamp":1764203488,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月26日，荣昌生物(09995)股东将股票由法国巴黎银行转入香港上海汇丰银行，转仓市值8.96亿港元，占比5.29%。建银国际近日发布研报称，将荣昌生物目标价，由110港元调高9%至120港元，维持“跑赢大市”的投资评级。建银国际表示，基本上维持对荣昌生物2025年/2026年/2027年总营收的预测不变，分别为28亿元人民币/34亿元人民币/46亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","00005","BK1574","BK4207","03143","LU0634319403.HKD","LU0516422440.USD","LU0516422952.EUR","LU2148510915.USD","LU0516422366.SGD","BK4521","BK1161","HSHD.SI","LU0310800965.SGD","LU0052756011.USD","LU1481107354.HKD","BK0239","LU0540923850.HKD","BK4585","LU0516423174.USD","BK1601","09995","LU2328871848.SGD","LU1267930227.SGD","BK1610","BK1572","LU0348735423.USD","LU0417516738.SGD","LU0164880469.USD","LU1969619763.USD","LU0149721374.USD","LU0128525689.USD","BK4588","BK1583","688331","LU2236285917.USD","LU1064131003.USD","HSBA.UK","LU0516423091.SGD","LU1064130708.USD","HSBC","BK1231"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767352643670,"stockEarnings":[{"period":"1week","weight":-0.0387},{"period":"1month","weight":-0.1832},{"period":"3month","weight":-0.3344},{"period":"6month","weight":0.091},{"period":"1year","weight":1.5835},{"period":"ytd","weight":1.5835}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15248人(较上一季度增加18.39%)","perCapita":"10645股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56371万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}